A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723

Conditions

Mucopolysaccharidosis II

Keywords

Hunter syndrome, immunogenicity, antibodies

Brief summary

Study IDS116406 will be a non-interventional, phlebotomy study in Hunter Syndrome patients who are currently being treated with idursulfase, an enzyme replacement therapy, and in at least a single patient who is naïve to treatment, if possible to recruit. All patients enrolled into the study will have a single blood draw for the analysis of antibodies induced by this enzyme replacement therapy (idursulfase). Patient samples with positive responses to antibodies induced by idursulfase will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro. Each subject will have a screening visit, which may occur at their regularly scheduled out-patient visit. If the patient consents to participate in the study, a blood sample (total volume of approximately 3mL) for immunogenicity analysis will be drawn before their current treatment infusion

Detailed description

Study IDS116406 will be a non-interventional, phlebotomy study in Hunter Syndrome patients who are currently being treated with idursulfase, an enzyme replacement therapy, and in at least a single patient who is naïve to treatment, if possible to recruit. All patients enrolled into the study will have a single blood draw for the analysis of antibodies induced by this enzyme replacement therapy (idursulfase). Patient samples with positive responses to antibodies induced by idursulfase will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro. Each subject will have a screening visit, which may occur at their regularly scheduled out-patient visit. If the patient consents to participate in the study, a blood sample (total volume of approximately 3mL) for immunogenicity analysis will be drawn before their current treatment infusion

Related papers

No related papers found yet.

Interventions

DRUGIdursulfase

recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.

DRUGGSK2788723

GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

A subject will be eligible for inclusion in this study only if patient meets criteria 1 and 2 or 1 and 3: * Diagnosed with Hunter syndrome * Patients with Hunter syndrome who are being treated with idursulfase * Patients with Hunter syndrome who are naïve of idursulfase treatment (if possible\*) \*This study will also attempt to recruit 1 patient who has never received idursulfase. If a naïve patient has not been identified within an agreed amount of time between GSK and the investigator, the study will concluded without this sample

Exclusion criteria

* Subjects who are currently participating in another clinical trial are not permitted to be enrolled in this study.

Design outcomes

Primary

Measure	Time frame	Description
Level and capability of binding and neutralizing antibodies induced by idursulfase after the administration of idursulfase	1 Day	To assess the cross-reactivity of the antibodies induced by idursulfase to GSK2788723, in vitro

Countries

Japan

Outcome results

None listed